Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
 58th Annual Meeting - EconoTimes)
AUSTIN, Texas, Nov. 03, 2016 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat genetic rare diseases and cancer, today announced that it will present preclinical results from studies evaluating AEB3103, which targets a vulnerability of cancer metabolism for the treatment of hematological malignancies, at the 58th Annual American Society of Hematology (ASH) Meeting being held December 3-6, 2016 in San Diego, California.
Treatment with AEB3103, an engineered human enzyme that degrades the amino acid cysteine/cystine resulting in selective oxidative stress for malignant cells, demonstrated in preclinical studies an increased median survival time in a mouse model of chronic lymphocytic leukemia (CLL) compared with an approved front line therapy, fludarabine. Additionally, treatment with AEB3103 inhibited cell growth in several models, including in vitro cultures of patient-derived CLL and multiple myeloma cells, as well as ex vivo cultures of patient-derived acute lymphocytic leukemia and acute myeloid leukemia cells.
Full abstracts are available online at www.hematology.org. Details of the upcoming poster presentation are listed below.
Abstract Title (#1587): Development of a human therapeutic L-Cyst(e)ine-degrading enzyme for the treatment of hematological malignancies
Session Title: 605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases: Poster I
Date: Saturday, December 3, 2016
Presentation Time: 5:30 p.m. - 7:30 p.m. PT
Location: San Diego Convention Center, Hall GH
About Aeglea BioTherapeutics
Aeglea is a biotechnology company committed to developing engineered human enzymes for the treatment of rare diseases and cancer associated with abnormal amino acid metabolism. The company’s engineered human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in genetic rare diseases or to starve tumors dependent on amino acids by reducing levels below the normal range. Aeglea’s clinical program for its lead product candidate, AEB1102, includes three Phase 1 clinical trials, studying AEB1102 for the treatment of patients with Arginase I deficiency, advanced solid tumors and hematological malignancies. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for a genetic rare disease, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine. For more information, visit http://aegleabio.com.
Media Contact: Kelly Boothe, Ph.D. BrewLife 415.946.1076 [email protected] Investor Contact: Charles N. York II Chief Financial Officer Aeglea BioTherapeutics [email protected]
